title: Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure.
abstract: In this work, we report a novel surface plasmon resonance (SPR) based live-cell biosensing platform to measure and compare the binding affinity of vascular endothelial growth factor (VEGF) to vascular endothelial growth factor receptor (VEGFR) and VEGF to bevacizumab. Results have shown that bevacizumab binds VEGF with a higher association rate and affinity compared to VEGFR. Further, this platform has been employed to mimic the in vivo condition of the VEGF-VEGFR angiogenic switch. Competitive binding to VEGF between VEGFR and bevacizumab was monitored in real-time using this platform. Results demonstrated a significant blockage of VEGF-VEGFR binding by bevacizumab. From the results, it is evident that the proposed strategy is simple and highly sensitive for the direct and real-time measurements of bevacizumab drug efficacy to the VEGF-VEGFR angiogenic switch in living SKOV-3 cells.
authors.affiliation: Nanobioengineering/Bioelectronics Laboratory, Department of Biomedical Engineering, Florida International University , Miami, Florida, 33174, United States.
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
authors.forename: Subbiah
authors.initials: S
authors.lastname: Alwarappan
authors.forename: Haitham A
authors.initials: HA
authors.lastname: Badr
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.forename: Hongyun
authors.initials: H
authors.lastname: Liu
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Zhu
authors.forename: Chen-Zhong
authors.initials: CZ
authors.lastname: Li
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000068258:Bevacizumab; D015374:Biosensing Techniques; D007700:Kinetics; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D020349:Surface Plasmon Resonance / Q000379:methods*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor